Identification of the anti-tumor activity and mechanisms of nuciferine through a network pharmacology approach
Aim: Nuciferine is an aporphine alkaloid extracted from lotus leaves, which is a raw material in Chinese medicinal herb for weight loss. In this study we used a network pharmacology approach to identify the anti-tumor activity of nuciferine and the underlying mechanisms. Methods: The pharmacological...
Saved in:
Published in | Acta pharmacologica Sinica Vol. 37; no. 7; pp. 963 - 972 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
Nature Publishing Group UK
01.07.2016
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
ISSN | 1671-4083 1745-7254 1745-7254 |
DOI | 10.1038/aps.2016.53 |
Cover
Abstract | Aim: Nuciferine is an aporphine alkaloid extracted from lotus leaves, which is a raw material in Chinese medicinal herb for weight loss. In this study we used a network pharmacology approach to identify the anti-tumor activity of nuciferine and the underlying mechanisms. Methods: The pharmacological activities and mechanisms of nuciferine were identified through target profile prediction, clustering analysis and functional enrichment analysis using our traditional Chinese medicine (TCM) network pharmacology platform. The anti- tumor activity of nuciferine was validated by in vitro and in vivo experiments. The anti-tumor mechanisms of nuciferine were predicted through network target analysis and verified by in vitro experiments. Results: The nuciferine target profile was enriched with signaling pathways and biological functions, including "regulation of lipase activity", "response to nicotine" and "regulation of cell proliferation". Target profile clustering results suggested that nuciferine to exert anti-tumor effect. In experimental validation, nuciferine (0.8 mg/mL) markedly inhibited the viability of human neuroblastoma SY5Y cells and mouse colorectal cancer CT26 cells in vitro, and nuciferine (0.05 mg/mL) significantly suppressed the invasion of 6 cancer cell lines in vitro. Intraperitoneal injection of nuciferine (9.5 mg/mL, ip, 3 times a week for 3 weeks) significantly decreased the weight of SYSY and CT26 tumor xenografts in nude mice. Network target analysis and experimental validation in SY5Y and CT26 cells showed that the anti-tumor effect of nuciferine was mediated through inhibiting the PI3K-AKT signaling pathway and IL-1 levels in SY5Y and CT26 cells. Conclusion: By using a TCM network pharmacology method, nuciferine is neuroblastoma and mouse colorectal cancer in vitro and in vivo, through dentified as an anti-tumor agent against human nhibiting the PI3K-AKT signaling pathways and IL-1 levels |
---|---|
AbstractList | Aim:
Nuciferine is an aporphine alkaloid extracted from lotus leaves, which is a raw material in Chinese medicinal herb for weight loss. In this study we used a network pharmacology approach to identify the anti-tumor activity of nuciferine and the underlying mechanisms.
Methods:
The pharmacological activities and mechanisms of nuciferine were identified through target profile prediction, clustering analysis and functional enrichment analysis using our traditional Chinese medicine (TCM) network pharmacology platform. The anti-tumor activity of nuciferine was validated by
in vitro
and
in vivo
experiments. The anti-tumor mechanisms of nuciferine were predicted through network target analysis and verified by
in vitro
experiments.
Results:
The nuciferine target profile was enriched with signaling pathways and biological functions, including “regulation of lipase activity”, “response to nicotine” and “regulation of cell proliferation”. Target profile clustering results suggested that nuciferine to exert anti-tumor effect. In experimental validation, nuciferine (0.8 mg/mL) markedly inhibited the viability of human neuroblastoma SY5Y cells and mouse colorectal cancer CT26 cells
in vitro
, and nuciferine (0.05 mg/mL) significantly suppressed the invasion of 6 cancer cell lines
in vitro
. Intraperitoneal injection of nuciferine (9.5 mg/mL, ip, 3 times a week for 3 weeks) significantly decreased the weight of SY5Y and CT26 tumor xenografts in nude mice. Network target analysis and experimental validation in SY5Y and CT26 cells showed that the anti-tumor effect of nuciferine was mediated through inhibiting the PI3K-AKT signaling pathway and IL-1 levels in SY5Y and CT26 cells.
Conclusion:
By using a TCM network pharmacology method, nuciferine is identified as an anti-tumor agent against human neuroblastoma and mouse colorectal cancer
in vitro
and
in vivo
, through inhibiting the PI3K-AKT signaling pathways and IL-1 levels. Aim: Nuciferine is an aporphine alkaloid extracted from lotus leaves, which is a raw material in Chinese medicinal herb for weight loss. In this study we used a network pharmacology approach to identify the anti-tumor activity of nuciferine and the underlying mechanisms. Methods: The pharmacological activities and mechanisms of nuciferine were identified through target profile prediction, clustering analysis and functional enrichment analysis using our traditional Chinese medicine (TCM) network pharmacology platform. The anti- tumor activity of nuciferine was validated by in vitro and in vivo experiments. The anti-tumor mechanisms of nuciferine were predicted through network target analysis and verified by in vitro experiments. Results: The nuciferine target profile was enriched with signaling pathways and biological functions, including "regulation of lipase activity", "response to nicotine" and "regulation of cell proliferation". Target profile clustering results suggested that nuciferine to exert anti-tumor effect. In experimental validation, nuciferine (0.8 mg/mL) markedly inhibited the viability of human neuroblastoma SY5Y cells and mouse colorectal cancer CT26 cells in vitro, and nuciferine (0.05 mg/mL) significantly suppressed the invasion of 6 cancer cell lines in vitro. Intraperitoneal injection of nuciferine (9.5 mg/mL, ip, 3 times a week for 3 weeks) significantly decreased the weight of SYSY and CT26 tumor xenografts in nude mice. Network target analysis and experimental validation in SY5Y and CT26 cells showed that the anti-tumor effect of nuciferine was mediated through inhibiting the PI3K-AKT signaling pathway and IL-1 levels in SY5Y and CT26 cells. Conclusion: By using a TCM network pharmacology method, nuciferine is neuroblastoma and mouse colorectal cancer in vitro and in vivo, through dentified as an anti-tumor agent against human nhibiting the PI3K-AKT signaling pathways and IL-1 levels Aim: Nuciferine is an aporphine alkaloid extracted from lotus leaves, which is a raw material in Chinese medicinal herb for weight loss. In this study we used a network pharmacology approach to identify the anti-tumor activity of nuciferine and the underlying mechanisms. Methods: The pharmacological activities and mechanisms of nuciferine were identified through target profile prediction, clustering analysis and functional enrichment analysis using our traditional Chinese medicine (TCM) network pharmacology platform. The anti-tumor activity of nuciferine was validated by in vitro and in vivo experiments. The anti-tumor mechanisms of nuciferine were predicted through network target analysis and verified by in vitro experiments. Results: The nuciferine target profile was enriched with signaling pathways and biological functions, including "regulation of lipase activity", "response to nicotine" and "regulation of cell proliferation". Target profile clustering results suggested that nuciferine to exert anti-tumor effect. In experimental validation, nuciferine (0.8 mg/mL) markedly inhibited the viability of human neuroblastoma SY5Y cells and mouse colorectal cancer CT26 cells in vitro, and nuciferine (0.05 mg/mL) significantly suppressed the invasion of 6 cancer cell lines in vitro. Intraperitoneal injection of nuciferine (9.5 mg/mL, ip, 3 times a week for 3 weeks) significantly decreased the weight of SY5Y and CT26 tumor xenografts in nude mice. Network target analysis and experimental validation in SY5Y and CT26 cells showed that the anti-tumor effect of nuciferine was mediated through inhibiting the PI3K-AKT signaling pathway and IL-1 levels in SY5Y and CT26 cells. Conclusion: By using a TCM network pharmacology method, nuciferine is identified as an anti-tumor agent against human neuroblastoma and mouse colorectal cancer in vitro and in vivo, through inhibiting the PI3K-AKT signaling pathways and IL-1 levels. Nuciferine is an aporphine alkaloid extracted from lotus leaves, which is a raw material in Chinese medicinal herb for weight loss. In this study we used a network pharmacology approach to identify the anti-tumor activity of nuciferine and the underlying mechanisms. The pharmacological activities and mechanisms of nuciferine were identified through target profile prediction, clustering analysis and functional enrichment analysis using our traditional Chinese medicine (TCM) network pharmacology platform. The anti-tumor activity of nuciferine was validated by in vitro and in vivo experiments. The anti-tumor mechanisms of nuciferine were predicted through network target analysis and verified by in vitro experiments. The nuciferine target profile was enriched with signaling pathways and biological functions, including "regulation of lipase activity", "response to nicotine" and "regulation of cell proliferation". Target profile clustering results suggested that nuciferine to exert anti-tumor effect. In experimental validation, nuciferine (0.8 mg/mL) markedly inhibited the viability of human neuroblastoma SY5Y cells and mouse colorectal cancer CT26 cells in vitro, and nuciferine (0.05 mg/mL) significantly suppressed the invasion of 6 cancer cell lines in vitro. Intraperitoneal injection of nuciferine (9.5 mg/mL, ip, 3 times a week for 3 weeks) significantly decreased the weight of SY5Y and CT26 tumor xenografts in nude mice. Network target analysis and experimental validation in SY5Y and CT26 cells showed that the anti-tumor effect of nuciferine was mediated through inhibiting the PI3K-AKT signaling pathway and IL-1 levels in SY5Y and CT26 cells. By using a TCM network pharmacology method, nuciferine is identified as an anti-tumor agent against human neuroblastoma and mouse colorectal cancer in vitro and in vivo, through inhibiting the PI3K-AKT signaling pathways and IL-1 levels. Nuciferine is an aporphine alkaloid extracted from lotus leaves, which is a raw material in Chinese medicinal herb for weight loss. In this study we used a network pharmacology approach to identify the anti-tumor activity of nuciferine and the underlying mechanisms.AIMNuciferine is an aporphine alkaloid extracted from lotus leaves, which is a raw material in Chinese medicinal herb for weight loss. In this study we used a network pharmacology approach to identify the anti-tumor activity of nuciferine and the underlying mechanisms.The pharmacological activities and mechanisms of nuciferine were identified through target profile prediction, clustering analysis and functional enrichment analysis using our traditional Chinese medicine (TCM) network pharmacology platform. The anti-tumor activity of nuciferine was validated by in vitro and in vivo experiments. The anti-tumor mechanisms of nuciferine were predicted through network target analysis and verified by in vitro experiments.METHODSThe pharmacological activities and mechanisms of nuciferine were identified through target profile prediction, clustering analysis and functional enrichment analysis using our traditional Chinese medicine (TCM) network pharmacology platform. The anti-tumor activity of nuciferine was validated by in vitro and in vivo experiments. The anti-tumor mechanisms of nuciferine were predicted through network target analysis and verified by in vitro experiments.The nuciferine target profile was enriched with signaling pathways and biological functions, including "regulation of lipase activity", "response to nicotine" and "regulation of cell proliferation". Target profile clustering results suggested that nuciferine to exert anti-tumor effect. In experimental validation, nuciferine (0.8 mg/mL) markedly inhibited the viability of human neuroblastoma SY5Y cells and mouse colorectal cancer CT26 cells in vitro, and nuciferine (0.05 mg/mL) significantly suppressed the invasion of 6 cancer cell lines in vitro. Intraperitoneal injection of nuciferine (9.5 mg/mL, ip, 3 times a week for 3 weeks) significantly decreased the weight of SY5Y and CT26 tumor xenografts in nude mice. Network target analysis and experimental validation in SY5Y and CT26 cells showed that the anti-tumor effect of nuciferine was mediated through inhibiting the PI3K-AKT signaling pathway and IL-1 levels in SY5Y and CT26 cells.RESULTSThe nuciferine target profile was enriched with signaling pathways and biological functions, including "regulation of lipase activity", "response to nicotine" and "regulation of cell proliferation". Target profile clustering results suggested that nuciferine to exert anti-tumor effect. In experimental validation, nuciferine (0.8 mg/mL) markedly inhibited the viability of human neuroblastoma SY5Y cells and mouse colorectal cancer CT26 cells in vitro, and nuciferine (0.05 mg/mL) significantly suppressed the invasion of 6 cancer cell lines in vitro. Intraperitoneal injection of nuciferine (9.5 mg/mL, ip, 3 times a week for 3 weeks) significantly decreased the weight of SY5Y and CT26 tumor xenografts in nude mice. Network target analysis and experimental validation in SY5Y and CT26 cells showed that the anti-tumor effect of nuciferine was mediated through inhibiting the PI3K-AKT signaling pathway and IL-1 levels in SY5Y and CT26 cells.By using a TCM network pharmacology method, nuciferine is identified as an anti-tumor agent against human neuroblastoma and mouse colorectal cancer in vitro and in vivo, through inhibiting the PI3K-AKT signaling pathways and IL-1 levels.CONCLUSIONBy using a TCM network pharmacology method, nuciferine is identified as an anti-tumor agent against human neuroblastoma and mouse colorectal cancer in vitro and in vivo, through inhibiting the PI3K-AKT signaling pathways and IL-1 levels. |
Author | Quan QI Rui LI Hui-ying LI Yu-bing CAO Ming BAI Xiao-jing FAN Shu-yan WANG Bo ZHANG Shao LI |
AuthorAffiliation | Tianjin State Key Laboratory of Modem Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China MOE Key Lab of Bioinformatics, Bioinformatics Division, TNLIST and Department of Automation, Tsinghua University, Beijing 100084, China The Second Hospital Affiliated to Tianjin University of Traditional Chinese Medicine, Tianjin 300150, China Tianjin International Joint Academy of Biotechnology & Medicine, Tianjin 300457, China |
Author_xml | – sequence: 1 givenname: Quan surname: Qi fullname: Qi, Quan organization: Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Bioinformatics Division, TNLIST and Department of Automation, MOE Key Lab of Bioinformatics, Tsinghua University – sequence: 2 givenname: Rui surname: Li fullname: Li, Rui organization: Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Bioinformatics Division, TNLIST and Department of Automation, MOE Key Lab of Bioinformatics, Tsinghua University – sequence: 3 givenname: Hui-ying surname: Li fullname: Li, Hui-ying organization: Bioinformatics Division, TNLIST and Department of Automation, MOE Key Lab of Bioinformatics, Tsinghua University – sequence: 4 givenname: Yu-bing surname: Cao fullname: Cao, Yu-bing organization: Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine – sequence: 5 givenname: Ming surname: Bai fullname: Bai, Ming organization: Bioinformatics Division, TNLIST and Department of Automation, MOE Key Lab of Bioinformatics, Tsinghua University – sequence: 6 givenname: Xiao-jing surname: Fan fullname: Fan, Xiao-jing organization: The Second Hospital Affiliated to Tianjin University of Traditional Chinese Medicine – sequence: 7 givenname: Shu-yan surname: Wang fullname: Wang, Shu-yan organization: Tianjin International Joint Academy of Biotechnology & Medicine – sequence: 8 givenname: Bo surname: Zhang fullname: Zhang, Bo email: z-b07@mails.tsinghua.edu.cn organization: Bioinformatics Division, TNLIST and Department of Automation, MOE Key Lab of Bioinformatics, Tsinghua University, Tianjin International Joint Academy of Biotechnology & Medicine – sequence: 9 givenname: Shao surname: Li fullname: Li, Shao email: shaoli@mail.tsinghua.edu.cn organization: Bioinformatics Division, TNLIST and Department of Automation, MOE Key Lab of Bioinformatics, Tsinghua University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27180984$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkslv1DAUxiNURBc4cUcRXJAgg7d4uVRCFUulSlzgbL1xnIlLYqe2U9T_Hg8zjEoFEidbz7_v-XvLaXXkg7dV9RyjFUZUvoM5rQjCfNXSR9UJFqxtBGnZUblzgRuGJD2uTlO6RogSitWT6pgILJGS7KTyl5312fXOQHbB16Gv82BrKLEmL1OINZjsbl2-K7GunqwZwLs0pS3pF-N6G523RRTDshlqqL3NP0L8Xs8DxAlMGMOmaOc5BjDD0-pxD2Oyz_bnWfXt44evF5-bqy-fLi_eXzWmFSQ3neJSUbkG1REEneVSdGAUBd4C4R2lsqeYWsLXpiesl6zjtNQkeqyYsQToWXW-yzsv68l2ptQYYdRzdBPEOx3A6T9fvBv0JtxqpigVnJQEr_cJYrhZbMp6csnYcQRvw5J06Z_krcBY_g-KGS2wKuirB-h1WKIvndhSSCCMBC_Ui_vmD65_T60Ab3aAiSGlaPsDgpHe7oQuO6G3O6FbWmj8gDYu_5p2qdyN_9C83WlSyew3Nt4z-lf85f6LIfjNTVEcHHGuGMEUEfoTgSbV2g |
CitedBy_id | crossref_primary_10_3389_fphar_2018_00010 crossref_primary_10_1016_j_aca_2022_339772 crossref_primary_10_1016_j_apsusc_2023_158698 crossref_primary_10_1021_acs_jafc_0c04985 crossref_primary_10_3390_molecules23112899 crossref_primary_10_1186_s12986_021_00549_0 crossref_primary_10_1016_j_biopha_2023_115075 crossref_primary_10_1016_j_dib_2024_110962 crossref_primary_10_1155_2021_6665137 crossref_primary_10_3389_fonc_2022_838152 crossref_primary_10_3389_fphar_2021_613104 crossref_primary_10_1039_D2MO00158F crossref_primary_10_1016_j_jep_2024_118262 crossref_primary_10_1016_j_crphys_2021_12_004 crossref_primary_10_1155_2021_1353674 crossref_primary_10_1093_hr_uhac276 crossref_primary_10_1016_j_csbj_2019_02_002 crossref_primary_10_1016_j_jep_2021_114335 crossref_primary_10_1360_SSV_2021_0369 crossref_primary_10_1038_s41598_022_07087_6 crossref_primary_10_3390_ijms22189819 crossref_primary_10_1016_j_euroneuro_2018_07_096 crossref_primary_10_1360_SSI_2021_0243 crossref_primary_10_1016_j_jff_2021_104682 crossref_primary_10_1002_pca_3108 crossref_primary_10_1007_s11101_024_09943_x crossref_primary_10_1242_bio_060448 crossref_primary_10_3390_cancers14030529 crossref_primary_10_3390_plants12233923 crossref_primary_10_1016_j_canlet_2019_05_015 crossref_primary_10_1016_j_ejmech_2021_113857 crossref_primary_10_1186_s13046_019_1134_y crossref_primary_10_3389_fphar_2017_00939 crossref_primary_10_1016_j_phrs_2023_106820 crossref_primary_10_1016_j_jare_2023_11_003 crossref_primary_10_2174_1568026623666230111154537 crossref_primary_10_1007_s40261_018_0683_8 crossref_primary_10_3390_cancers10110461 crossref_primary_10_3389_fbinf_2022_928116 crossref_primary_10_3390_life13040893 crossref_primary_10_1177_1934578X1701200849 crossref_primary_10_1620_tjem_254_17 crossref_primary_10_3389_fvets_2022_939377 crossref_primary_10_1038_aps_2017_210 crossref_primary_10_3389_fphar_2021_632236 crossref_primary_10_2139_ssrn_3914869 crossref_primary_10_1002_ptr_5732 crossref_primary_10_1016_j_jep_2020_113429 crossref_primary_10_1021_acs_jafc_4c04818 crossref_primary_10_1016_j_jafr_2024_101362 crossref_primary_10_1016_j_scib_2023_05_023 crossref_primary_10_1007_s11030_023_10791_8 crossref_primary_10_1016_j_phymed_2022_154536 crossref_primary_10_1016_j_semcancer_2019_12_010 crossref_primary_10_1080_10408398_2021_2009436 crossref_primary_10_1016_j_tifs_2021_04_033 crossref_primary_10_3390_ijms241914532 crossref_primary_10_1016_j_indcrop_2022_114694 crossref_primary_10_1155_2017_1583185 crossref_primary_10_1016_j_jep_2016_12_042 crossref_primary_10_1007_s11356_022_19249_0 crossref_primary_10_3389_fphar_2018_01514 crossref_primary_10_1016_j_phrs_2021_106002 |
Cites_doi | 10.1093/nar/gki033 10.1073/pnas.1301814110 10.1002/pbc.20219 10.1038/nchembio.118 10.1021/jm0303711 10.2174/156800909789271521 10.1016/j.jep.2015.09.034 10.1093/nar/gkn923 10.1002/hep.27551 10.1007/BF00171991 10.1371/journal.pone.0011764 10.3390/molecules191117829 10.3724/SP.J.1009.2013.00110 10.1016/j.jep.2015.02.015 10.1016/S1044-579X(02)00014-7 10.1093/nar/gkn892 10.1038/75556 10.1056/NEJM199811053391901 10.1186/1471-2105-11-S11-S6 10.1142/S0192415X03001429 10.1021/ja00738a045 10.1055/s-0030-1250186 10.1038/nchembio.2007.53 10.1016/j.drudis.2008.02.001 10.1016/j.jep.2005.12.036 10.1093/nar/gkp896 10.1016/j.bmc.2012.11.038 10.3736/jcim20070501 10.1126/science.aab0642 10.1038/nchembio.216 |
ContentType | Journal Article |
Copyright | CPS and SIMM 2016 Copyright Nature Publishing Group Jul 2016 Copyright © 2016 CPS and SIMM 2016 CPS and SIMM |
Copyright_xml | – notice: CPS and SIMM 2016 – notice: Copyright Nature Publishing Group Jul 2016 – notice: Copyright © 2016 CPS and SIMM 2016 CPS and SIMM |
DBID | 2RA 92L CQIGP W91 ~WA AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QP 7QR 7T5 7TK 7TO 7U9 7X7 7XB 88E 8FD 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M7N M7P P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM |
DOI | 10.1038/aps.2016.53 |
DatabaseName | 维普期刊资源整合服务平台 中文科技期刊数据库-CALIS站点 中文科技期刊数据库-7.0平台 中文科技期刊数据库-医药卫生 中文科技期刊数据库- 镜像站点 CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Immunology Abstracts Neurosciences Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni) Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database (ProQuest) Biotechnology and BioEngineering Abstracts Proquest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student Oncogenes and Growth Factors Abstracts Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection Biological Science Collection AIDS and Cancer Research Abstracts Chemoreception Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE MEDLINE - Academic ProQuest Central Student |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
DocumentTitleAlternate | Identification of the anti-tumor activity and mechanisms of nuciferine through a network pharmacology approach |
EISSN | 1745-7254 |
EndPage | 972 |
ExternalDocumentID | PMC4933762 4105333361 27180984 10_1038_aps_2016_53 669421302 |
Genre | Journal Article |
GroupedDBID | --- -05 -0E -Q- -S~ .3N 0R~ 188 1OC 23M 2RA 2WC 31~ 36B 3V. 4.4 406 53G 5GY 5VR 5VS 6J9 70F 7X7 8-1 88E 8FI 8FJ 8R4 8R5 8RM 92L 92M 9D9 9DE A8Z AADWK AANZL AATNV AAWBL AAYFA AAYJO AAZLF ABAWZ ABGIJ ABKZE ABUWG ACAOD ACBMV ACBRV ACBYP ACGFO ACGFS ACIGE ACIWK ACKTT ACPRK ACRQY ACTTH ACVWB ACXQS ACZOJ ADBBV ADFRT ADHDB ADMDM ADQMX ADRAZ ADYYL AEDAW AEFTE AEJRE AENEX AESKC AEVLU AEXYK AFBPY AFKRA AFNRJ AFRAH AFSHS AFUIB AFZJQ AGAYW AGEZK AGGBP AGHAI AHMBA AHSBF AILAN AJAOE AJCLW AJDOV AJRNO ALFFA ALMA_UNASSIGNED_HOLDINGS AMRJV AMYLF AOIJS AXYYD BAWUL BBNVY BENPR BFHJK BHPHI BKKNO BPHCQ BVXVI C1A CAG CAJEE CAJUS CCEZO CCPQU CHBEP CIEJG CO8 COF CQIGP CS3 CW9 DIK DNIVK DPUIP E3Z EBLON EBS EE. EIOEI EJD EMB EMOBN ESTFP F5P FA0 FDQFY FERAY FIZPM FSGXE FYUFA GX1 HCIFZ HH5 HMCUK HYE HZI HZ~ IWAJR JSO JUIAU JZLTJ K97 KQ8 LH4 LW6 M1P M48 M7P MK0 NQJWS NXXTH NYICJ O9- OK1 OVD P2P P6G PQQKQ PROAC PSQYO Q-- Q-4 Q2X R-E RNT RNTTT RPM RT5 S.. SNX SNYQT SOHCF SRMVM SV3 SWTZT T8U TAOOD TBHMF TDRGL TEORI TR2 TSG U1F U1G U5E U5O UKHRP UZ5 W91 ~88 ~NG ~WA -SE AACDK AASML AAXDM ABAKF ABZZP ACMJI AEFQL AEMSY AFBBN AGQEE AIGIU ALIPV FIGPU LGEZI LOTEE NADUK ROL AAYXX ABBRH ABDBE ABFSG ACMFV ACSTC AEZWR AFDZB AFHIU AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT SOJ ABRTQ CGR CUY CVF ECM EIF NPM PJZUB PPXIY PQGLB 7QP 7QR 7T5 7TK 7TO 7U9 7XB 8FD 8FE 8FH 8FK AZQEC DWQXO FR3 GNUQQ H94 K9. LK8 M7N P64 PKEHL PQEST PQUKI PRINS PUEGO 7X8 5PM |
ID | FETCH-LOGICAL-c572t-d968938ba9d20ade687dac93a65a26d338f313e26bcf24f84d632717f194ce2a3 |
IEDL.DBID | M48 |
ISSN | 1671-4083 1745-7254 |
IngestDate | Thu Aug 21 17:52:03 EDT 2025 Fri Sep 05 05:47:55 EDT 2025 Fri Sep 05 12:27:11 EDT 2025 Sat Aug 23 14:49:31 EDT 2025 Mon Jul 21 06:03:23 EDT 2025 Tue Jul 01 02:18:33 EDT 2025 Thu Apr 24 23:10:56 EDT 2025 Fri Feb 21 02:40:29 EST 2025 Wed Feb 14 10:17:43 EST 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Keywords | nuciferine colorectal cancer IL-1 neuroblastoma drugCIPHER TCM network pharmacology anti-tumor agent PI3K-AKT |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c572t-d968938ba9d20ade687dac93a65a26d338f313e26bcf24f84d632717f194ce2a3 |
Notes | Aim: Nuciferine is an aporphine alkaloid extracted from lotus leaves, which is a raw material in Chinese medicinal herb for weight loss. In this study we used a network pharmacology approach to identify the anti-tumor activity of nuciferine and the underlying mechanisms. Methods: The pharmacological activities and mechanisms of nuciferine were identified through target profile prediction, clustering analysis and functional enrichment analysis using our traditional Chinese medicine (TCM) network pharmacology platform. The anti- tumor activity of nuciferine was validated by in vitro and in vivo experiments. The anti-tumor mechanisms of nuciferine were predicted through network target analysis and verified by in vitro experiments. Results: The nuciferine target profile was enriched with signaling pathways and biological functions, including "regulation of lipase activity", "response to nicotine" and "regulation of cell proliferation". Target profile clustering results suggested that nuciferine to exert anti-tumor effect. In experimental validation, nuciferine (0.8 mg/mL) markedly inhibited the viability of human neuroblastoma SY5Y cells and mouse colorectal cancer CT26 cells in vitro, and nuciferine (0.05 mg/mL) significantly suppressed the invasion of 6 cancer cell lines in vitro. Intraperitoneal injection of nuciferine (9.5 mg/mL, ip, 3 times a week for 3 weeks) significantly decreased the weight of SYSY and CT26 tumor xenografts in nude mice. Network target analysis and experimental validation in SY5Y and CT26 cells showed that the anti-tumor effect of nuciferine was mediated through inhibiting the PI3K-AKT signaling pathway and IL-1 levels in SY5Y and CT26 cells. Conclusion: By using a TCM network pharmacology method, nuciferine is neuroblastoma and mouse colorectal cancer in vitro and in vivo, through dentified as an anti-tumor agent against human nhibiting the PI3K-AKT signaling pathways and IL-1 levels nuciferine; TCM network pharmacology; anti-tumor agent; neuroblastoma; colorectal cancer; PI3K-AKT; IL-1; drugClPHER 31-1347/R ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 These two authors contributed equally to this work. |
OpenAccessLink | https://www.nature.com/articles/aps201653.pdf |
PMID | 27180984 |
PQID | 1800701076 |
PQPubID | 28815 |
PageCount | 10 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4933762 proquest_miscellaneous_1808657118 proquest_miscellaneous_1801436579 proquest_journals_1800701076 pubmed_primary_27180984 crossref_primary_10_1038_aps_2016_53 crossref_citationtrail_10_1038_aps_2016_53 springer_journals_10_1038_aps_2016_53 chongqing_primary_669421302 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2016-07-01 |
PublicationDateYYYYMMDD | 2016-07-01 |
PublicationDate_xml | – month: 07 year: 2016 text: 2016-07-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | London |
PublicationPlace_xml | – name: London – name: United States – name: Shanghai |
PublicationTitle | Acta pharmacologica Sinica |
PublicationTitleAbbrev | Acta Pharmacol Sin |
PublicationTitleAlternate | Acta Pharmacologica Sinica |
PublicationYear | 2016 |
Publisher | Nature Publishing Group UK Nature Publishing Group |
Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group |
References | Liu, Yi, Guo, Xiang, Deng, He (CR17) 2015; 165 Zhao, Li (CR12) 2010; 5 Ohlson (CR5) 2008; 13 Li, Zhang (CR8) 2013; 11 Hsiao, Liu (CR6) 2010; 76 Nakamura, Nakashima, Tanabe, Oda, Yokota, Fujimoto (CR16) 2013; 21 Huang da, Sherman, Lempicki (CR22) 2009; 37 Ashburner, Ball, Blake, Botstein, Butler, Cherry (CR27) 2000; 25 Wu, Wang, Weng, Yen (CR36) 2003; 31 Li, Zhang, Jiang, Wei, Zhang (CR13) 2010; 11 Fulda (CR31) 2009; 9 Wu, Wu (CR10) 2015; 13 Soignet, Maslak, Wang, Jhanwar, Calleja, Dardashti (CR2) 1998; 339 Young, Bender, Hoyt, McWhinnie, Chirn, Tao (CR34) 2008; 4 Zhang, Liu, Zhao, Wang, Liu, Li (CR14) 2013; 2013 Su, Luo, Zhu, Fu, Zhao, Chen (CR33) 2015; 61 Apte, Voronov (CR32) 2002; 12 Kanehisa, Goto, Furumichi, Tanabe, Hirakawa (CR23) 2010; 38 Rix, Superti-Furga (CR26) 2009; 5 Hopkins (CR7) 2008; 4 Li (CR11) 2015; 350 Bai, Xu, Chen, Liu, Gu, Wang (CR4) 2013; 110 Knight, Goodman, Taylor, Macdonald, Coltman, Constanzi (CR20) 1990; 8 Pritchard, Cotterill, Germond, Imeson, de Kraker, Jones (CR19) 2005; 44 Zhang, Wang, Li (CR21) 2013; 2013 Zhang, Xiao, Xu, Zhou, Zhou, Wang (CR37) 2006; 24 Ono, Hattori, Fukaya, Imai, Ohizumi (CR35) 2006; 106 Liu, Kao, Wu, Li, Huang, Li (CR18) 2014; 19 Hamosh, Scott, Amberger, Bocchini, McKusick (CR28) 2005; 33 Keshava Prasad, Goel, Kandasamy, Keerthikumar, Kumar, Mathivanan (CR24) 2009; 37 Posner, McRiner, Paik, Sur, Borstnik, Xie (CR1) 2004; 47 Taubes (CR25) 2012; 335 Meng, Liu (CR38) 2014; 35 Zhang, Lu, Bai, He, Tan, Bian (CR15) 2015; 175 Wani, Taylor, Wall, Coggon, McPhail (CR3) 1971; 93 Li (CR9) 2007; 5 Lin, Hou, Jin, Yu, Yang (CR30) 2008; 13 Tu, Li, Yang, Zou (CR29) 2001; 13 XM Wu (BFaps201653_CR10) 2015; 13 U Rix (BFaps201653_CR26) 2009; 5 F Bai (BFaps201653_CR4) 2013; 110 M Kanehisa (BFaps201653_CR23) 2010; 38 CM Liu (BFaps201653_CR18) 2014; 19 WL Hsiao (BFaps201653_CR6) 2010; 76 S Li (BFaps201653_CR13) 2010; 11 S Nakamura (BFaps201653_CR16) 2013; 21 S Li (BFaps201653_CR9) 2007; 5 B Zhang (BFaps201653_CR21) 2013; 2013 W Liu (BFaps201653_CR17) 2015; 165 B Su (BFaps201653_CR33) 2015; 61 S Fulda (BFaps201653_CR31) 2009; 9 Y Ono (BFaps201653_CR35) 2006; 106 J Zhang (BFaps201653_CR37) 2006; 24 MC Wani (BFaps201653_CR3) 1971; 93 DW Young (BFaps201653_CR34) 2008; 4 TS Keshava Prasad (BFaps201653_CR24) 2009; 37 G Taubes (BFaps201653_CR25) 2012; 335 S Lin (BFaps201653_CR30) 2008; 13 MJ Wu (BFaps201653_CR36) 2003; 31 SL Soignet (BFaps201653_CR2) 1998; 339 X Meng (BFaps201653_CR38) 2014; 35 B Zhang (BFaps201653_CR15) 2015; 175 GH Posner (BFaps201653_CR1) 2004; 47 CC Tu (BFaps201653_CR29) 2001; 13 S Zhao (BFaps201653_CR12) 2010; 5 S Li (BFaps201653_CR8) 2013; 11 M Ashburner (BFaps201653_CR27) 2000; 25 A Hamosh (BFaps201653_CR28) 2005; 33 W Huang da (BFaps201653_CR22) 2009; 37 RN Apte (BFaps201653_CR32) 2002; 12 J Pritchard (BFaps201653_CR19) 2005; 44 S Li (BFaps201653_CR11) 2015; 350 S Ohlson (BFaps201653_CR5) 2008; 13 B Zhang (BFaps201653_CR14) 2013; 2013 WA Knight (BFaps201653_CR20) 1990; 8 AL Hopkins (BFaps201653_CR7) 2008; 4 14971910 - J Med Chem. 2004 Feb 26;47(5):1299-301 19754357 - Curr Cancer Drug Targets. 2009 Sep;9(6):729-37 23270663 - Bioorg Med Chem. 2013 Feb 1;21(3):779-87 23787177 - Chin J Nat Med. 2013 Mar;11(2):110-20 18936753 - Nat Chem Biol. 2008 Nov;4(11):682-90 23440190 - Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4273-8 19033363 - Nucleic Acids Res. 2009 Jan;37(1):1-13 20635308 - Planta Med. 2010 Aug;76(11):1118-31 19690537 - Nat Chem Biol. 2009 Sep;5(9):616-24 21172056 - BMC Bioinformatics. 2010 Dec 14;11 Suppl 11:S6 25660283 - Chin J Nat Med. 2015 Jan;13(1):1-2 23653662 - Evid Based Complement Alternat Med. 2013;2013:456747 22223787 - Science. 2012 Jan 6;335(6064):28, 30-2 26435225 - J Ethnopharmacol. 2015 Dec 4;175:638-47 23476684 - Evid Based Complement Alternat Med. 2013;2013:278405 25294684 - Hepatology. 2015 Feb;61(2):585-97 18988627 - Nucleic Acids Res. 2009 Jan;37(Database issue):D767-72 5553076 - J Am Chem Soc. 1971 May 5;93(9):2325-7 9801394 - N Engl J Med. 1998 Nov 5;339(19):1341-8 20668676 - PLoS One. 2010 Jul 26;5(7):e11764 16495025 - J Ethnopharmacol. 2006 Jun 30;106(2):238-44 15546135 - Pediatr Blood Cancer. 2005 Apr;44(4):348-57 18468561 - Drug Discov Today. 2008 May;13(9-10):433-9 18066055 - Nat Chem Biol. 2008 Jan;4(1):59-68 17854545 - Zhong Xi Yi Jie He Xue Bao. 2007 Sep;5(5):489-93 10802651 - Nat Genet. 2000 May;25(1):25-9 25372397 - Molecules. 2014 Nov 03;19(11):17829-38 14696672 - Am J Chin Med. 2003;31(5):687-98 2380020 - Invest New Drugs. 1990;8 Suppl 1:S87-9 25698245 - J Ethnopharmacol. 2015 May 13;165:83-93 12147202 - Semin Cancer Biol. 2002 Aug;12(4):277-90 15608251 - Nucleic Acids Res. 2005 Jan 1;33(Database issue):D514-7 19880382 - Nucleic Acids Res. 2010 Jan;38(Database issue):D355-60 |
References_xml | – volume: 33 start-page: D514 year: 2005 end-page: 7 ident: CR28 article-title: Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders publication-title: Nucleic Acids Res doi: 10.1093/nar/gki033 – volume: 110 start-page: 4273 year: 2013 end-page: 8 ident: CR4 article-title: Free energy landscape for the binding process of Huperzine A to acetylcholinesterase publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1301814110 – volume: 24 start-page: 759 year: 2006 end-page: 61 ident: CR37 article-title: The research of nuciferin's antiarrhythmic effect publication-title: Herald Med – volume: 44 start-page: 348 year: 2005 end-page: 57 ident: CR19 article-title: High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group publication-title: Pediatr Blood Cancer doi: 10.1002/pbc.20219 – volume: 4 start-page: 682 year: 2008 end-page: 90 ident: CR7 article-title: Network pharmacology: the next paradigm in drug discovery publication-title: Nat Chem Biol doi: 10.1038/nchembio.118 – volume: 47 start-page: 1299 year: 2004 end-page: 301 ident: CR1 article-title: Anticancer and antimalarial efficacy and safety of artemisinin-derived trioxane dimers in rodents publication-title: J Med Chem doi: 10.1021/jm0303711 – volume: 9 start-page: 729 year: 2009 end-page: 37 ident: CR31 article-title: The PI3K/Akt/mTOR pathway as therapeutic target in neuroblastoma publication-title: Curr Cancer Drug Targets doi: 10.2174/156800909789271521 – volume: 175 start-page: 638 year: 2015 end-page: 47 ident: CR15 article-title: Tetramethylpyrazine identified by a network pharmacology approach ameliorates methotrexate-induced oxidative organ injury publication-title: J Ethnopharmacol doi: 10.1016/j.jep.2015.09.034 – volume: 37 start-page: 1 year: 2009 end-page: 13 ident: CR22 article-title: Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists publication-title: Nucleic Acids Res doi: 10.1093/nar/gkn923 – volume: 2013 start-page: 456747 year: 2013 ident: CR21 article-title: An integrative platform of TCM network pharmacology and its application on a herbal formula, Qing-Luo-Yin publication-title: Evid Based Complement Alternat Med – volume: 61 start-page: 585 year: 2015 end-page: 97 ident: CR33 article-title: Interleukin-1β/IRAK-1 inflammatory signaling contributes to persistent Gankyrin activation during hepatocarcinogenesis publication-title: Hepatology doi: 10.1002/hep.27551 – volume: 8 start-page: S87 year: 1990 end-page: 9 ident: CR20 article-title: Phase II trial of intravenous melphalan for metastatic colorectal carcinoma. A Southwest Oncology Group study publication-title: Invest New Drugs doi: 10.1007/BF00171991 – volume: 5 start-page: e 11764 year: 2010 ident: CR12 article-title: Network-based relating pharmacological and genomic spaces for drug target identification publication-title: PLoS One doi: 10.1371/journal.pone.0011764 – volume: 35 start-page: 119 year: 2014 end-page: 24 ident: CR38 article-title: Inhibitory effect of tea polyphenols on Caco-2 cells and their synergistic antioxidant activity with nuciferine publication-title: Food Sci – volume: 19 start-page: 17829 year: 2014 end-page: 38 ident: CR18 article-title: Antioxidant and anticancer aporphine alkaloids from the leaves of Gaertn. cv. Rosa-plena publication-title: Molecules doi: 10.3390/molecules191117829 – volume: 11 start-page: 110 year: 2013 end-page: 20 ident: CR8 article-title: Traditional Chinese medicine network pharmacology: theory, methodology and application publication-title: Chin J Nat Med doi: 10.3724/SP.J.1009.2013.00110 – volume: 2013 start-page: 278405 year: 2013 ident: CR14 article-title: Vitexicarpin acts as a novel angiogenesis inhibitor and its target network publication-title: Evid Based Complement Alternat Med – volume: 165 start-page: 83 year: 2015 end-page: 93 ident: CR17 article-title: Nuciferine, extracted from Gaertn, inhibits tumor-promoting effect of nicotine involving Wnt/β-catenin signaling in non-small cell lung cancer publication-title: J Ethnopharmacol doi: 10.1016/j.jep.2015.02.015 – volume: 12 start-page: 277 year: 2002 end-page: 90 ident: CR32 article-title: Interleukin-1--a major pleiotropic cytokine in tumor-host interactions publication-title: Semin Cancer Biol doi: 10.1016/S1044-579X(02)00014-7 – volume: 37 start-page: D767 year: 2009 end-page: 72 ident: CR24 article-title: Human protein reference database — 2009 update publication-title: Nucleic Acids Res doi: 10.1093/nar/gkn892 – volume: 25 start-page: 25 year: 2000 end-page: 9 ident: CR27 article-title: Gene ontology: tool for the unification of biology. The Gene Ontology Consortium publication-title: Nat Genet doi: 10.1038/75556 – volume: 339 start-page: 1341 year: 1998 end-page: 8 ident: CR2 article-title: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide publication-title: N Engl J Med doi: 10.1056/NEJM199811053391901 – volume: 11 start-page: S6 year: 2010 ident: CR13 article-title: Herb network construction and co-module analysis for uncovering the combination rule of traditional Chinese herbal formulae publication-title: BMC Bioinformatics doi: 10.1186/1471-2105-11-S11-S6 – volume: 31 start-page: 687 year: 2003 end-page: 98 ident: CR36 article-title: Antioxidant activity of methanol extract of the lotus leaf ( Gertn) publication-title: Am J Chin Med doi: 10.1142/S0192415X03001429 – volume: 93 start-page: 2325 year: 1971 end-page: 7 ident: CR3 article-title: Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from publication-title: J Am Chem Soc doi: 10.1021/ja00738a045 – volume: 76 start-page: 1118 year: 2010 end-page: 31 ident: CR6 article-title: The role of traditional Chinese herbal medicines in cancer therapy--from TCM theory to mechanistic insights publication-title: Planta Med doi: 10.1055/s-0030-1250186 – volume: 4 start-page: 59 year: 2008 end-page: 68 ident: CR34 article-title: Integrating high-content screening and ligand-target prediction to identify mechanism of action publication-title: Nat Chem Biol doi: 10.1038/nchembio.2007.53 – volume: 13 start-page: 138 year: 2008 end-page: 43 ident: CR30 article-title: Natural compound nuciferine activates chloride channel of wild type and F508 mutant cystic fibrosis transmembrane conductance regulator publication-title: Chin J Clin Pharmacol Ther – volume: 13 start-page: 433 year: 2008 end-page: 9 ident: CR5 article-title: Designing transient binding drugs: a new concept for drug discovery publication-title: Drug Discov Today doi: 10.1016/j.drudis.2008.02.001 – volume: 106 start-page: 238 year: 2006 end-page: 44 ident: CR35 article-title: Anti-obesity effect of leaves extract in mice and rats publication-title: J Ethnopharmacol doi: 10.1016/j.jep.2005.12.036 – volume: 38 start-page: D355 year: 2010 end-page: 60 ident: CR23 article-title: KEGG for representation and analysis of molecular networks involving diseases and drugs publication-title: Nucleic Acids Res doi: 10.1093/nar/gkp896 – volume: 21 start-page: 779 year: 2013 end-page: 87 ident: CR16 article-title: Alkaloid constituents from flower buds and leaves of sacred lotus ( , Nymphaeaceae) with melanogenesis inhibitory activity in B16 melanoma cells publication-title: Bioorg Med Chem doi: 10.1016/j.bmc.2012.11.038 – volume: 5 start-page: 489 year: 2007 end-page: 93 ident: CR9 article-title: Framework and practice of network-based studies for Chinese herbal formula publication-title: Zhong Xi Yi Jie He Xue Bao doi: 10.3736/jcim20070501 – volume: 13 start-page: 120 year: 2001 end-page: 1 ident: CR29 article-title: Experimental study of lotus leaf alkaloids role in weight loss in obese rats with hyperlipidemia publication-title: J JiangXi Coll Tradit Chin Med – volume: 350 start-page: S72 year: 2015 end-page: 4 ident: CR11 article-title: Mapping ancient remedies: applying a network approach to traditional Chinese medicine publication-title: Science doi: 10.1126/science.aab0642 – volume: 335 start-page: 30 year: 2012 end-page: 2 ident: CR25 article-title: Cancer research. Unraveling the obesity — cancer connection publication-title: Science – volume: 5 start-page: 616 year: 2009 end-page: 24 ident: CR26 article-title: Target profiling of small molecules by chemical proteomics publication-title: Nat Chem Biol doi: 10.1038/nchembio.216 – volume: 13 start-page: 1 year: 2015 end-page: 2 ident: CR10 article-title: Network pharmacology: a new approach to unveiling Traditional Chinese medicine publication-title: Chin J Nat Med – volume: 110 start-page: 4273 year: 2013 ident: BFaps201653_CR4 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1301814110 – volume: 11 start-page: 110 year: 2013 ident: BFaps201653_CR8 publication-title: Chin J Nat Med doi: 10.3724/SP.J.1009.2013.00110 – volume: 175 start-page: 638 year: 2015 ident: BFaps201653_CR15 publication-title: J Ethnopharmacol doi: 10.1016/j.jep.2015.09.034 – volume: 165 start-page: 83 year: 2015 ident: BFaps201653_CR17 publication-title: J Ethnopharmacol doi: 10.1016/j.jep.2015.02.015 – volume: 13 start-page: 120 year: 2001 ident: BFaps201653_CR29 publication-title: J JiangXi Coll Tradit Chin Med – volume: 93 start-page: 2325 year: 1971 ident: BFaps201653_CR3 publication-title: J Am Chem Soc doi: 10.1021/ja00738a045 – volume: 5 start-page: 489 year: 2007 ident: BFaps201653_CR9 publication-title: Zhong Xi Yi Jie He Xue Bao doi: 10.3736/jcim20070501 – volume: 8 start-page: S87 year: 1990 ident: BFaps201653_CR20 publication-title: Invest New Drugs doi: 10.1007/BF00171991 – volume: 2013 start-page: 278405 year: 2013 ident: BFaps201653_CR14 publication-title: Evid Based Complement Alternat Med – volume: 335 start-page: 30 year: 2012 ident: BFaps201653_CR25 publication-title: Science – volume: 31 start-page: 687 year: 2003 ident: BFaps201653_CR36 publication-title: Am J Chin Med doi: 10.1142/S0192415X03001429 – volume: 5 start-page: e 11764 year: 2010 ident: BFaps201653_CR12 publication-title: PLoS One doi: 10.1371/journal.pone.0011764 – volume: 350 start-page: S72 year: 2015 ident: BFaps201653_CR11 publication-title: Science doi: 10.1126/science.aab0642 – volume: 19 start-page: 17829 year: 2014 ident: BFaps201653_CR18 publication-title: Molecules doi: 10.3390/molecules191117829 – volume: 44 start-page: 348 year: 2005 ident: BFaps201653_CR19 publication-title: Pediatr Blood Cancer doi: 10.1002/pbc.20219 – volume: 4 start-page: 59 year: 2008 ident: BFaps201653_CR34 publication-title: Nat Chem Biol doi: 10.1038/nchembio.2007.53 – volume: 9 start-page: 729 year: 2009 ident: BFaps201653_CR31 publication-title: Curr Cancer Drug Targets doi: 10.2174/156800909789271521 – volume: 13 start-page: 138 year: 2008 ident: BFaps201653_CR30 publication-title: Chin J Clin Pharmacol Ther – volume: 13 start-page: 433 year: 2008 ident: BFaps201653_CR5 publication-title: Drug Discov Today doi: 10.1016/j.drudis.2008.02.001 – volume: 61 start-page: 585 year: 2015 ident: BFaps201653_CR33 publication-title: Hepatology doi: 10.1002/hep.27551 – volume: 47 start-page: 1299 year: 2004 ident: BFaps201653_CR1 publication-title: J Med Chem doi: 10.1021/jm0303711 – volume: 13 start-page: 1 year: 2015 ident: BFaps201653_CR10 publication-title: Chin J Nat Med – volume: 76 start-page: 1118 year: 2010 ident: BFaps201653_CR6 publication-title: Planta Med doi: 10.1055/s-0030-1250186 – volume: 38 start-page: D355 year: 2010 ident: BFaps201653_CR23 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkp896 – volume: 2013 start-page: 456747 year: 2013 ident: BFaps201653_CR21 publication-title: Evid Based Complement Alternat Med – volume: 21 start-page: 779 year: 2013 ident: BFaps201653_CR16 publication-title: Bioorg Med Chem doi: 10.1016/j.bmc.2012.11.038 – volume: 37 start-page: D767 year: 2009 ident: BFaps201653_CR24 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkn892 – volume: 106 start-page: 238 year: 2006 ident: BFaps201653_CR35 publication-title: J Ethnopharmacol doi: 10.1016/j.jep.2005.12.036 – volume: 24 start-page: 759 year: 2006 ident: BFaps201653_CR37 publication-title: Herald Med – volume: 25 start-page: 25 year: 2000 ident: BFaps201653_CR27 publication-title: Nat Genet doi: 10.1038/75556 – volume: 35 start-page: 119 year: 2014 ident: BFaps201653_CR38 publication-title: Food Sci – volume: 37 start-page: 1 year: 2009 ident: BFaps201653_CR22 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkn923 – volume: 12 start-page: 277 year: 2002 ident: BFaps201653_CR32 publication-title: Semin Cancer Biol doi: 10.1016/S1044-579X(02)00014-7 – volume: 5 start-page: 616 year: 2009 ident: BFaps201653_CR26 publication-title: Nat Chem Biol doi: 10.1038/nchembio.216 – volume: 339 start-page: 1341 year: 1998 ident: BFaps201653_CR2 publication-title: N Engl J Med doi: 10.1056/NEJM199811053391901 – volume: 4 start-page: 682 year: 2008 ident: BFaps201653_CR7 publication-title: Nat Chem Biol doi: 10.1038/nchembio.118 – volume: 11 start-page: S6 year: 2010 ident: BFaps201653_CR13 publication-title: BMC Bioinformatics doi: 10.1186/1471-2105-11-S11-S6 – volume: 33 start-page: D514 year: 2005 ident: BFaps201653_CR28 publication-title: Nucleic Acids Res doi: 10.1093/nar/gki033 – reference: 19880382 - Nucleic Acids Res. 2010 Jan;38(Database issue):D355-60 – reference: 2380020 - Invest New Drugs. 1990;8 Suppl 1:S87-9 – reference: 18988627 - Nucleic Acids Res. 2009 Jan;37(Database issue):D767-72 – reference: 23787177 - Chin J Nat Med. 2013 Mar;11(2):110-20 – reference: 19754357 - Curr Cancer Drug Targets. 2009 Sep;9(6):729-37 – reference: 23653662 - Evid Based Complement Alternat Med. 2013;2013:456747 – reference: 26435225 - J Ethnopharmacol. 2015 Dec 4;175:638-47 – reference: 25660283 - Chin J Nat Med. 2015 Jan;13(1):1-2 – reference: 15608251 - Nucleic Acids Res. 2005 Jan 1;33(Database issue):D514-7 – reference: 18936753 - Nat Chem Biol. 2008 Nov;4(11):682-90 – reference: 22223787 - Science. 2012 Jan 6;335(6064):28, 30-2 – reference: 25698245 - J Ethnopharmacol. 2015 May 13;165:83-93 – reference: 23440190 - Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4273-8 – reference: 9801394 - N Engl J Med. 1998 Nov 5;339(19):1341-8 – reference: 19690537 - Nat Chem Biol. 2009 Sep;5(9):616-24 – reference: 18066055 - Nat Chem Biol. 2008 Jan;4(1):59-68 – reference: 16495025 - J Ethnopharmacol. 2006 Jun 30;106(2):238-44 – reference: 21172056 - BMC Bioinformatics. 2010 Dec 14;11 Suppl 11:S6 – reference: 25372397 - Molecules. 2014 Nov 03;19(11):17829-38 – reference: 15546135 - Pediatr Blood Cancer. 2005 Apr;44(4):348-57 – reference: 19033363 - Nucleic Acids Res. 2009 Jan;37(1):1-13 – reference: 14971910 - J Med Chem. 2004 Feb 26;47(5):1299-301 – reference: 10802651 - Nat Genet. 2000 May;25(1):25-9 – reference: 5553076 - J Am Chem Soc. 1971 May 5;93(9):2325-7 – reference: 14696672 - Am J Chin Med. 2003;31(5):687-98 – reference: 23270663 - Bioorg Med Chem. 2013 Feb 1;21(3):779-87 – reference: 17854545 - Zhong Xi Yi Jie He Xue Bao. 2007 Sep;5(5):489-93 – reference: 12147202 - Semin Cancer Biol. 2002 Aug;12(4):277-90 – reference: 20635308 - Planta Med. 2010 Aug;76(11):1118-31 – reference: 23476684 - Evid Based Complement Alternat Med. 2013;2013:278405 – reference: 18468561 - Drug Discov Today. 2008 May;13(9-10):433-9 – reference: 25294684 - Hepatology. 2015 Feb;61(2):585-97 – reference: 20668676 - PLoS One. 2010 Jul 26;5(7):e11764 |
SSID | ssj0032319 |
Score | 2.3928244 |
Snippet | Aim: Nuciferine is an aporphine alkaloid extracted from lotus leaves, which is a raw material in Chinese medicinal herb for weight loss. In this study we used... Aim: Nuciferine is an aporphine alkaloid extracted from lotus leaves, which is a raw material in Chinese medicinal herb for weight loss. In this study we used... Nuciferine is an aporphine alkaloid extracted from lotus leaves, which is a raw material in Chinese medicinal herb for weight loss. In this study we used a... Aim:Nuciferine is an aporphine alkaloid extracted from lotus leaves, which is a raw material in Chinese medicinal herb for weight loss. In this study we used a... Aim: Nuciferine is an aporphine alkaloid extracted from lotus leaves, which is a raw material in Chinese medicinal herb for weight loss. In this study we used... |
SourceID | pubmedcentral proquest pubmed crossref springer chongqing |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 963 |
SubjectTerms | Animals Antineoplastic Agents - pharmacology Aporphines - pharmacology Biomedical and Life Sciences Biomedicine Cell Line, Tumor Cell Survival - drug effects Cluster Analysis Drugs, Chinese Herbal - pharmacology Humans Immunology Internal Medicine Medical Microbiology Mice Mice, Nude Neoplasm Invasiveness Original original-article Pharmacology/Toxicology Phosphatidylinositol 3-Kinases - metabolism Signal Transduction - drug effects Vaccine Xenograft Model Antitumor Assays 医药网络 抗肿瘤活性 机制 活性鉴定 生物碱 神经母细胞瘤 药理学 荷叶 |
SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT9wwELZaemgvVd9NociVKIeKlCR2_DhVCIFQDxUHkPZmeW2nXYlNFrJ74N93JnGybLfimozy8Iw933g83xBykLMK_BiXac6CTrn0KrUuiJQLzwBwWO5dx_b5S1xc85-TchI33Np4rHJYE7uF2jcO98iPc4XMNBCsiB-L2xS7RmF2NbbQeEqeddRlYM9yMgZcDLALwt9cSIyTFIv1eRlTx3aBXN25-I5dkZ_DSlP_vgVfsemdtiDn9snJf9KnnVc6f0VeRjhJT3r9vyZPQv2GHF72fNT3R_RqXV7VHtFDerlmqr5_S-q-TLeK-3a0qSjgQQqDPUuXq3lzR7HsAbtLwDVP5wHLhGftvEXJeuXwWAygVBqb_VBL6_5UOV08eA8deMvfkevzs6vTizQ2YEhdKYtl6rUAOKOmVvsisz4IJb11mllR2gKUyVQFCg2FmLqq4JXiXrAC4sMq1xwbjbH3ZKdu6vCR0NILrWFxVQFCoKDwmVklhatcYN6yLCG7oxLMoifaMEJoXmBmNSHfBrUYF7nLsYXGjely6EwZ0KdBfZqSJeRgFB6e9F-xvUG_Js7b1qytLCFfxtsw4zCNYuvQrDoZAJmilPpRGQUSEL0l5ENvMuO3wAipTCueELlhTKMAMn5v3qlnfzrmb64ZOAQYjq-D2T349O1f_PT4L-6SFyjYHz7eIzvLu1X4DBBrOd3v5tFfkTcoLQ priority: 102 providerName: ProQuest |
Title | Identification of the anti-tumor activity and mechanisms of nuciferine through a network pharmacology approach |
URI | http://lib.cqvip.com/qk/95561A/201607/669421302.html https://link.springer.com/article/10.1038/aps.2016.53 https://www.ncbi.nlm.nih.gov/pubmed/27180984 https://www.proquest.com/docview/1800701076 https://www.proquest.com/docview/1801436579 https://www.proquest.com/docview/1808657118 https://pubmed.ncbi.nlm.nih.gov/PMC4933762 |
Volume | 37 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9tAEB7yuPRS-q6axGwhzaFEqaVdrXYPpcQlJhRqTInBN7HWrhJDLDt-QP3vM6NX4jjkZPCOZXlm1vONZucbgOOAZxjHROwH3GlfxFb5JnXSF9JyBBxG2LRg--zJy4H4M4yGO1AP46wUuHg2taN5UoP57dn_u_Uv3PA_y5Zx9cPMiHc7kGcR34V9DEmSsrC_oikncAQxhINxgRImxatGvScfJnqFm2l-fYdBYzNMbWHP7SOUT-qoRXjqvoHXFa5k56UjvIUdl7-Dk35JTL0-ZVcPfVaLU3bC-g-U1ev3kJf9uln1AI9NM4bAkKHWx_5yNZnOGfU_0JgJfM-yiaN-4fFisiDJfJXS-RiEq6ya-sMMy8vj5Wz26HtYTWD-AQbdi6vfl341icFPozhc-lZLxDVqZLQN28Y6qWJrUs2NjEyIVuUqQ8u6UI7SLBSZElbyEBPFLNCCJo7xj7CXT3P3GVhkpdb4L6sc5kJO0TXbWSzTLHXcGt724KAxQjIrGTcSKbUIqcTqwffaLElakZjTLI3bpCimc5WgPROyZxJxD44b4fpKz4od1vZNav9LAkVESJgbSw--Nsu49aieYnI3XRUyiDZlFOsXZRRKYBrnwafSZZp7QQ2ptlbCg3jDmRoBov7eXMnHNwUFuNAcIwOq41vtdo9uffsnfnlRqQfwiuTKQ8iHsLecr9wRQq3lqAW78TBuwf55t9Pp4Wvnotf_1yo21z02SC4I |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6V9FAuiDemBRap7QHV1Pau1-sDQjxapbREEUql3szGu4ZIxE6bRCh_it_IjF9pCOqt13i8WXtm5-GZ-QZg1-cZ2jERuT63sSsio1ydWukKaTg6HFqYtET77MnuufhyEV5swJ-mF4bKKhudWCpqU6T0jfzQV4RMg8GKfD-5dGlqFGVXmxEalVic2sVvDNmm704-I3_3guD4aPCp69ZTBdw0jIKZa2KJNloNdWwCTxsrVWR0GnMtQx3gDrnKcJc2kMM0C0SmhJE8wKAnw3CfpmdxXPcObArqaO3A5sejXv9bo_s5ekvkcPsyoshM8boj0OPqUE8IHdyXb2kO8xbqtvzHJVqnVXu45uSu12r-k7At7eDxfbhXO7DsQyVxD2DD5g9hv18hYC8O2GDZ0DU9YPusv8TGXjyCvGoMzuovhazIGHqgDNk7cmfzcXHFqNGC5lngb4aNLTUmj6bjKVHm85QKcdAvZvV4IaZZXtWxs8m1_2ENUvpjOL8V5jyBTl7k9hmw0Mg4RnWuLAZdVtGaXhbJNEstN5p7Dmy3TEgmFbRHImUsAsrlOvCmYUuS1mjpNLTjV1Jm7blKkJ8J8TMJuQO7LXGz0n_Jdhr-JrWmmCZLuXbgdXsZzzglbnRui3lJg26tDKP4RhqFFBgvOvC0Epl2L_iGlBcr4UC0IkwtAWGMr17JRz9LrHERczRB-Dr2GrG7tvX1R3x-8yO-gq3u4OtZcnbSO92Gu3RTVfq8A53Z1dy-QAdvNnxZnyoG32_7IP8FvjJmZg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9NADLfGkGAviG_CBhzStge0rEkuubs8IIQY1cbQ1IdN6lu45i5QaU26pRXqv8Zfh52vrhTtba-Nc73E9tmO7Z8Bdn2eoR0LpetzG7uhNMrVqRVuKAxHh0OHJq3QPs_E8UX4bRgNN-BP2wtDZZXtmVgd1KZI6Rt5z1eETIPBiuhlTVnE4Kj_aXrl0gQpyrS24zRqETm1i98YvpUfT46Q13tB0P96_uXYbSYMuGkkg5lrYoH2Wo10bAJPGyuUNDqNuRaRDnC3XGW4YxuIUZoFYaZCI3iAAVCGoT9N0uK47j24Lzl6VahLctgFexz9JnK9fSEpRlO86Q30uOrpKeGE--KQJjI_xFMu_3mFdmrVMq65u-tVm_-kbiuL2H8MjxpXln2uZe8JbNj8KewPaizsxQE7X7Z2lQdsnw2WKNmLZ5DXLcJZ882QFRlDX5Qho8fubD4prhm1XNBkC_zNsImlFuVxOSmJMp-nVJKDHjJrBg0xzfK6op1Nb_wPazHTn8PFnbDmBWzmRW5fAYuMiGM82JXF8MsqWtPLpEiz1HKjuefAdseEZFqDfCRCxGFAWV0HPrRsSdIGN53Gd1wmVf6eqwT5mRA_k4g7sNsRtyv9l2yn5W_SnBllspRwB953l1HbKYWjc1vMKxp0cEUk41tpFFJg5OjAy1pkur3gG1JerEIH5IowdQSENr56JR__qlDHw5ijMcLXsdeK3Y2trz_i69sf8R08QPVNvp-cnW7DFt1T10DvwObsem7foKc3G72tVIrBj7vW4b8bhmkt |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Identification+of+the+anti-tumor+activity+and+mechanisms+of+nuciferine+through+a+network+pharmacology+approach&rft.jtitle=%E4%B8%AD%E5%9B%BD%E8%8D%AF%E7%90%86%E5%AD%A6%E6%8A%A5%EF%BC%9A%E8%8B%B1%E6%96%87%E7%89%88&rft.au=Quan+QI+Rui+LI+Hui-ying+LI+Yu-bing+CAO+Ming+BAI+Xiao-jing+FAN+Shu-yan+WANG+Bo+ZHANG+Shao+LI&rft.date=2016-07-01&rft.issn=1671-4083&rft.eissn=1745-7254&rft.issue=7&rft.spage=963&rft.epage=972&rft_id=info:doi/10.1038%2Faps.2016.53&rft.externalDocID=669421302 |
thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F95561A%2F95561A.jpg |